Skip to main
XFOR
XFOR logo

XFOR Stock Forecast & Price Target

XFOR Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

X4 Pharmaceuticals Inc. has enhanced its enrollment target for the pivotal 4WARD study to 176 participants, aiming to provide a robust data package for regulatory review and improve its chances for successful outcomes in reducing annualized infection rates associated with its lead candidate, mavorixafor. The company is poised for significant market expansion, particularly into additional primary immunodeficiency disorders, supported by the biological validation of CXCR4 inhibition and a strong pathway for commercialization. Furthermore, the recent PIPE transaction and the anticipated restructuring of the existing debt position the company for improved financial flexibility and a stronger cash position, thus enhancing its overall investment appeal.

Bears say

X4 Pharmaceuticals's stock outlook is negatively impacted by significant adjustments to the company's financial projections, including a drastic reduction in target sales estimates for its lead therapy, mavorixafor. Key concerns include extended patient enrollment timelines for the 4WARD trial, which may hinder revenue growth, along with the anticipated dilution from ongoing financing activities. Additionally, the company's balance sheet remains a persistent burden, with an urgent need for strategic reviews and clarity regarding future capital requirements looming over investor sentiment.

XFOR has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of X4 Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About X4 Pharmaceuticals Inc (XFOR) Forecast

Analysts have given XFOR a Strong Buy based on their latest research and market trends.

According to 3 analysts, XFOR has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

X4 Pharmaceuticals Inc (XFOR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.